Publication & Citation Trends
Most Cited Works
Publications
34 total
Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor–associated tumors
Cited by 155
OpenAlex
Cytoskeletal stiffness, friction, and fluidity of cancer cell lines with different metastatic potential
Cited by 125
OpenAlex
Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies PDF
Cited by 194
OpenAlex
A Phase I Dose-Escalation Study of Tivantinib (ARQ 197) in Adult Patients with Metastatic Solid Tumors
Cited by 87
OpenAlex
Rescue of paclitaxel sensitivity by repression of Prohibitin1 in drug-resistant cancer cells PDF
Cited by 102
OpenAlex
Enhanced Analysis of Metastatic Prostate Cancer Using Stable Isotopes and High Mass Accuracy Instrumentation
Cited by 72
OpenAlex
Regulation of cell proliferation by the antizyme inhibitor: evidence for an antizyme-independent mechanism PDF
Cited by 53
OpenAlex
Suppression by cathepsin L inhibitors of the invasion of amnion membranes by murine cancer cells.
Cited by 101
OpenAlex
Research Topics
Cancer Genomics and Diagnostics
(8)
Lung Cancer Treatments and Mutations
(4)
Cancer-related Molecular Pathways
(3)
Glycosylation and Glycoproteins Research
(3)
Cancer, Hypoxia, and Metabolism
(3)
Frequent Co-Authors
Affiliations
Ontario Institute for Cancer Research
National Health Service
Brigham and Women's Hospital
Boston Children's Hospital
Mount Sinai Hospital